Brief: Mabion To Conduct Due Diligence For Potential Acquisition Of Facility In U.S.
11/09/2026 09:48
BRIEF-Mabion To Conduct Due Diligence For Potential Acquisition Of Facility In U.S. Sept 11 (Reuters) - Mabion SA MABP.WA:
TO CONDUCT DUE DILIGENCE FOR POTENTIAL ACQUISITION OF FACILITY IN USA
IN TALKS WITH POLISH AND INTERNATIONAL INVESTORS FOR FINANCING
ACQUISITION OF FACILITY WILL SHORTEN PATH FOR COMPANY TO LAUNCH CONTRACT MANUFACTURING OF BIOLOGICAL DRUGS IN US AND ENABLE UTILIZATION OF FACILITY’S EXISTING MARKET TIES WITH BIG PHARMA
Source text: ID:nEM7N6fZfa
Further company coverage: MABP.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Mabion SA
See all newsBrief: Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP
Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Q2 Net Loss At 15 Mln Zlotys
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects